Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

European Journal of Clinical Pharmacology
O SpigsetR Dahlqvist

Abstract

The purpose of this study was to investigate whether the disposition of fluvoxamine is associated with the CYP2D6 and CYP2C19 phenotype polymorphisms. The serum concentration of fluvoxamine was followed for 48 h after oral administration of a single dose of 50 mg fluvoxamine to five poor metabolizers of the CYP2D6 test drug dextromethorphan, five poor metabolizers of the CYP2C19 test drug mephenytoin, and five extensive metabolizers of both test drugs. Poor metabolizers of dextromethorphan had significantly higher areas under the serum concentration-time curve than extensive metabolizers of dextromethorphan (mean 1.31 vs 1.00 mumol.h.l-1). There were no differences between poor and extensive metabolizers of mephenytoin (mean, 1.00 vs 1.15 mumol.h.l-1). The results are consistent with a possible minor to moderate role of CYP2D6, but not CYP2C19, in fluvoxamine metabolism.

Citations

May 3, 2005·Der Nervenarzt·J KirchheinerM Bauer
Jun 20, 2006·European Archives of Psychiatry and Clinical Neuroscience·Norbert Thuerauf, Jens Lunkenheimer
Mar 19, 1999·European Journal of Pharmacology·M NorlénP Allard
Feb 16, 2000·Pharmacology & Therapeutics·C Hiemke, S Härtter
Jan 29, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Meera VaswaniSubramanyam Ramesh
Jun 6, 2007·The Pharmacogenomics Journal·D Tomalik-ScharteJ Kirchheiner
Mar 22, 2001·British Journal of Clinical Pharmacology·S HäggR Dahlqvist
Sep 12, 2002·Drug Metabolism and Drug Interactions·Michael W JanDavid A Flockhart
Sep 8, 2000·Clinical Pharmacokinetics·J A Carrillo, J Benitez
Sep 12, 2009·Clinical Pharmacokinetics·F F Tessa VerversAlfred F A M Schobben
Jul 9, 2011·Expert Opinion on Drug Metabolism & Toxicology·Stefano PorcelliDiana De Ronchi
Dec 9, 2008·Clinics in Laboratory Medicine·Angela Seeringer, Julia Kirchheiner
Jan 6, 2004·Fundamental & Clinical Pharmacology·Edoardo SpinaConcetta D'Arrigo
May 28, 2011·Journal of Veterinary Pharmacology and Therapeutics·N LiuS-X Jiang
Mar 18, 2010·British Journal of Clinical Pharmacology·Rocco OrlandoPietro Palatini
May 15, 2015·Clinical Pharmacology and Therapeutics·J K HicksUNKNOWN Clinical Pharmacogenetics Implementation Consortium
May 23, 2007·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·James ScottNatalie O'Brien
May 9, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M Miura, T Ohkubo
Mar 31, 2005·Journal of Pharmaceutical and Biomedical Analysis·Jeong-Wook Kwon, Kevin L Armbrust
Oct 3, 1998·Clinical Pharmacology and Therapeutics·A D KashubaJ S Bertino
Nov 4, 2008·Therapeutic Drug Monitoring·Junzo WatanabeToshiyuki Someya
Nov 25, 2005·European Journal of Clinical Pharmacology·M Strolin BenedettiF Tonner
Aug 5, 2005·The Journal of Pharmacology and Experimental Therapeutics·Kentarou UshijimaShigehiro Ohdo
Sep 24, 1999·The Journal of the Acoustical Society of America·R V ShannonJ Wygonski
Dec 10, 1999·Journal of Clinical Psychopharmacology·J A CarrilloJ Benítez
Oct 3, 1999·Journal of Clinical Psychopharmacology·D J GreenblattR I Shader
Aug 26, 1998·Therapeutic Drug Monitoring·S HärtterC Hiemke
May 21, 2005·Therapeutic Drug Monitoring·Toshiki KuniiKoichi Otani
Mar 28, 1998·British Journal of Clinical Pharmacology·O SpigsetR Dahlqvist
Dec 28, 2019·Pharmaceutics·Stefano FortinguerraAlessandro Buriani
Jun 9, 2006·Medicina clínica·Hortensia Alonso-NavarroJosé A García-Agúndez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.